Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be presented during a ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager and H.C.

Researchers have discovered that a common form of high blood pressure is caused by tiny, non-cancerous growths in the adrenal ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

Topline data were announced from a trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Kyushu University researchers have uncovered a surprising layer of complexity in aldosterone-producing adenomas (APAs)-adrenal gland tumors that drive high blood pressure. Using cutting-edge analysis ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Addison’s disease is a rare condition in which the adrenal glands do not produce enough of the hormones cortisol and ...

Spironolactone is a diuretic (water pill) commonly used to treat heart failure and high blood pressure, but it can also be ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.